Analyst Price Target is GBX 2,655
▲ +32.49% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Hikma Pharmaceuticals in the last 3 months. The average price target is GBX 2,655, with a high forecast of GBX 2,750 and a low forecast of GBX 2,560. The average price target represents a 32.49% upside from the last price of GBX 2,004.
Current Consensus is
Buy
The current consensus among 3 contributing investment analysts is to buy stock in Hikma Pharmaceuticals. This rating changed within the last month from a Moderate Buy consensus rating.
At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly. We are a trusted, reliable partner and dependable source of over 670 (as of 31 December 2021) high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe. We have 32 manufacturing facilities, 7 R&D centres and 8,700+ employees worldwide.
Read More
